Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

d half of 2010.
  • In October 2009, Lexicon completed the public offering and sale of 38.3 million shares of its common stock at $1.50 per share.  The net proceeds of the offering were $55.2 million, after deducting underwriting discounts and offering expenses.  

    • LX1031 and LX1032 are being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

    Financial Results

    Revenues:  Lexicon's revenues for the three months ended December 31, 2009 decreased 78 percent to $1.4 million from $6.4 million for the corresponding period in 2008.  The decrease was primarily attributable to reduced revenues under Lexicon's alliances with N.V. Organon, Bristol-Myers Squibb and Genentech, Inc., partially offset by increases in revenue under the company's collaboration with Taconic Farms, Inc.  For the year ended December 31, 2009, revenues decreased 67 percent to $10.7 million from $32.3 million for the corresponding period in 2008. '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
    8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
    9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
    10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
    11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
    (Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
    (Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
    (Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
    Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
    ... ... - Speeds ,Race for Time, to Find ... - Saves Valuable Research Money, LAS VEGAS, ... New York, are pleased to announce they have inked a,worldwide partnering agreement to commercialize ...
    ... the international,investment house specialising in medical sciences, said ... UK biotech sector,despite the most severe market conditions., ... and a development,of Merlin Biosciences, was instrumental in ... specialist dermatology company, to make a,significant product acquisition ...
    ... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... today announced that it will,host a Research Day ... EDT. A,webcast of the presentations will be available ... -- Strategic Company Overview, Jonathan Lim, M.D., President ...
    Cached Biology Technology:Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize 2Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize 3Excalibur - 'Transforming' Biotech Deals can Still be Achieved 2Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
    (Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
    (Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
    (Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
    Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
    ... and sea levels in the centuries to come? Are we ... the oceans on the rise? Can aquaculture be environmentally sustainable? ... of coastal fisheries? , Most importantly, what can governments, industry ... news media are invited to join leading international researchers and ...
    ... used to create early-stage sperm cells for the first time, ... about how sperm cells are created. , The research ... Reproduction: Gamete Biology, was carried out in Germany* by a ... the University of Göttingen but now of the North-east England ...
    ... immuno-contraceptive vaccine causes an animal's immune system to produce ... in the reproductive process. The antibodies can act against ... or the production of sperm and ova. ... nearly 20 years ago, regard it as more humane ...
    Cached Biology News:Are we killing the world's oceans? 2Early-stage sperm cells created from human bone marrow 2Manipulating nature: Scientists query wildlife birth-control method 2
    ... (AMV RT) catalyzes the polymerization of DNA ... (1). It requires a primer (DNA primers ... well as Mg2+ or Mn2+. The enzyme ... nonionic detergents and sulfhydryl compounds stabilize the ...
    ... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
    DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
    ... coli strain containing an overproducing clone of ... Transcriptase catalyzes the polymerization of DNA using ... copies of large mRNAs, >10 kb, may ... much lower RNase H activity than AMV ...
    Biology Products: